ClinicalTrials.gg
RecruitingNCT06681142PACE-OAUpdated Oct 27, 2026

Pharmacist-physiotherapist Collaborative Management for Early Knee Osteoarthritis

An interventional study of Pharmacy-Physiotherapy Intervention in Osteoarthritis (OA) of the Knee, Physiotherapy and Pharmacy, sponsored by University of Alberta. Recruiting at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of Alberta · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 27, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Osteoarthritis with a site in Canada — 25 open to participants now, 46 under way, 4 of them phase 3. Osteoarthritis · Canada.

Planned enrollment
75th of 176
125 · median 98
Started
2025
with 8 others
No phase
101 of 205
16 open now
Primary completion
2026-12
later than 13 of 45 live
Registered
190th of 205
by date
Lead sponsor
8 of 205
University of Alberta

Among the 205 studies in Osteoarthritis with a site in Canada, this one is the 75th largest by planned enrollment of the 176 interventional ones that give a count, is one of 9 that started in 2025, is one of 101 with no phase, reaches primary completion later than 13 of the 45 other live ones, and was the 190th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

25 of the 205 studies in Osteoarthritis with a site in Canada are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Osteoarthritis with a site in Canada, or all of them as a file.
02

Study summary

Osteoarthritis (OA) is a slowly progressive chronic condition that is associated with aging and is characterized as joint pain. Individuals with early-stage OA usually do not seek medical attention. If and when they do, patients more often present to a pharmacy for over-the-counter medications.

The investigators want to leverage community pharmacists' accessibility and scope of practice to best support patients with early knee OA. Given there are no disease-modifying treatments for OA, treatment guidelines center on patient education, self-management, and exercise, with medications playing a supporting role. Self-management is an effective strategy that provides a solid foundation for managing this progressive chronic condition and health care professionals like physiotherapists and pharmacists can help with the development and application of these skills.

Read the detailed description

Pharmacists will identify patients with knee pain using two recruitment strategies: (1) Posters placed near the dispensary and 'shelf talkers' placed near the over-the-counter non- steroidal anti-inflammatory drugs, acetaminophen, and natural health products (e.g. glucosamine, collagen) will recommend patients with knee pain talk to their pharmacist and (2) Patients receiving care by a pharmacist for other conditions that have similar risk factors as OA will be asked about symptomatic knee OA (e.g. obesity).

The inclusion criteria is patients 50 years of age or older who have been regularly experiencing pain, aching, or stiffness in and/or around the knee for at least 1 month. The exclusion criteria is patients with prior knee surgery, history of acute knee injury (6 months), unable or unwilling to attend physiotherapy, previous physician diagnoses of inflammatory arthritis or fibromyalgia, and unable to speak/ read English.

For those patients with probable symptomatic knee OA, the study will be explained and upon agreement, written consent will be secured. Following enrollment, the pharmacist will ask participants to complete the baseline assessments (in pharmacy or online):

  • Knee injury and OA Outcome Score (KOOS) -Reason for visiting the pharmacy
  • Socio-demographics (DOB, sex/gender, education, marital status, employment) -Past medical history (chronic conditions, current medications, height/weight, other joint involvement) -Previous medications/injections trialed for knee pain -Lifestyle activities (smoking, alcohol use, walking tolerance and any assistive walking devices) -Co-interventions (eg. chiropractor, joint injections, naturopath) -Self-management (Patient Activation Measure) The pharmacist will also answer questions that participants may have regarding services and medications.

Participants will be randomized to either the control arm which is usual care or the intervention arm which includes a referral to physiotherapy and a comprehensive medication review. Randomization will occur in variable computer-generated blocks of 4-8 participants. Following the enrolment, the pharmacist will receive a code that randomizes the patients into either the treatment group (comprehensive pharmacist assessment, pharmacologic recommendations, and education with referral to physiotherapy) or usual care (brief assessment and recommendation by the pharmacist, education information brochure).

If participants have a family physician, the pharmacist will provide a notice that the patient likely has knee OA and is enrolled in this study. The name of the pharmacist and physiotherapist will be provided.

03

Conditions studied

  • Osteoarthritis (OA) of the Knee
  • Physiotherapy
  • Pharmacy

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • regularly experiencing pain, aching, or stiffness in and/or around the knee for at least 1 month
  • complete the screening PhIT-OA questionnaire

Exclusion criteria

Exclusion Criteria:

  • Prior total knee replacement or on the waitlist to have your knee replaced
  • Knee surgery within the previous 4 months
  • History of acute injury to knee within previous 6 months
  • Unable to speak and read English
  • Unwilling or unable to visit a physiotherapist at a community physiotherapy clinic (specifically the dates and times of the partnering physiotherapy clinic)
  • Previous physician-diagnosed inflammatory arthritis (including this list): Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Lupus, Gout
  • Physician diagnosed fibromyalgia
  • A sudden, severely painful, hot, swollen joint at any time in the past
  • History of the following medications: csDMARD or bDMARD or tsDMARD, , Allopurinol or febuxostat, Colchicine
  • Received a knee joint injection in the past 3 months or have one scheduled in the next 3 months
  • Has completed the GLA:D Hip and Knee program at all in the past
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Investigator, Outcomes assessor)
Enrollment
125 participants (estimated)

Study arms

  • No intervention
    Usual Care (Control) Group

    Pharmacists will provide a general educational pamphlet and will inform the primary care physician of patient participation and referral for further assessment of knee OA. Participants randomized to this group will be offered physiotherapy and/or pharmacy interventions (individual or GLA:D program 3 months after enrollment) and pharmacy options (comprehensive medication review). It will be explained to participants that usual care is 'conservative therapy'. Usual care participants will be eligible to opt in for a comprehensive medication review (pharmacist) and/or the physiotherapy sessions and will be evaluated at 9-months after enrollment.

  • Experimental
    Intervention Group

    Pharmacists will provide comprehensive 1:1 patient care, including a SCHOLAR assessment and medication review, provide specific drug therapy recommendation(s) using shared decision making (SDM), and provide comprehensive patient education/resources. Pharmacists will refer to physiotherapy clinics located nearby for patient convenience and to establish community pharmacy/physiotherapy clinic relationships. Participants will be offered a physiotherapy assessment at a nearby physiotherapy clinic within 2 weeks of being assessed by the pharmacist. After the physiotherapy assessment session, participants who are diagnosed with symptomatic knee OA will be offered the GLA:D program for knee OA which includes 6-weeks of neuromuscular exercises along with 2 education session in a group format.

    Other: Pharmacy-Physiotherapy Intervention

Interventions

  • OtherPharmacy-Physiotherapy Intervention

    Pharmacists will provide comprehensive 1:1 patient care, including a complete patient assessment and medication review, provide specific drug therapy recommendation(s) using shared decision making (SDM), and provide patient education, including further written materials. Participants will be offered either individual or group physiotherapy sessions at the a private clinic.

06

What researchers measure

Primary outcomes

  1. Disease specific self-report measure for OA

    The Knee Injury in OA Outcome Score (KOOS) from 0-100 where a higher score is a better outcome.

    Time frame: Baseline, Post Intervention (3 & 6 month after baseline)

Secondary outcomes

  1. Patient Activation Measure (PAM)

    Scale from 0-100 where a higher score is a better outcome.

    Time frame: Baseline, Post Intervention (3 & 6 month after baseline)

07

Study locations

1 of 1 sites recruiting
  • Mint Health & Drugs Sherwood Park
    Sherwood Park, Alberta, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 15 months is below that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2024
First posted
Nov 8, 2024
StartActual
Aug 13, 2025
Primary completionEst.
Dec 1, 2026was Sep 2026
CompletionEst.
Dec 1, 2027was Sep 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Dec 1, 2026
Oct 27, 2026
Study completion
Sep 2027→Dec 1, 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Sep 2026→Dec 1, 2026
    Study completion Sep 2027→Dec 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06681142
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Aug 13, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Allyson Jones
Contact
cajones@ualberta.ca
780-492-2020
Jordyn Burgar
Contact
burgar@ucalgary.ca
Ross Tsuyuki
principal investigator · University of Alberta
Jill Hall
principal investigator · University of Alberta
Allyson Jones
principal investigator · University of Alberta

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion